vorasidenib
servier
['vorasidenib', 'indigo', 'ag-881']
. discusses the findings from the phase 3 indigo trial which were presented at the 2023 asco annual meeting. the study evaluated treatment with vorasidenib (ag-881), an idh1/2 inhibitor, in patients with low-grade glioma. via 
A leader in research, education and patient care in brain tumor, cerebrovascular, skull base, spine, pediatric, functional, and global health